Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 7, Issue 6, Pages 598-604Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2007.09.012
Keywords
-
Categories
Ask authors/readers for more resources
Irritable bowel syndrome (IBS) remains an incompletely understood, common syndrome with significant unmet medical needs. Significant progress has been made in the development of novel therapies aimed at normalizing bowel habit alterations and abdominal discomfort, even though some of the most effective treatments are currently only available for patients under a restricted access program from the FDA. Preclinical evidence supports the potential usefulness of several compounds in development for the treatment of chronic abdominal pain. Recent new evidence for a possible role of altered microflora and altered host microbial interactions may provide new treatment targets in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available